Clinical trial NCT01772251: Safety and Tolerability of Oshadi Icp In Patients With Type 1 Diabetes Mellitus - Phase Ib Clinical Study
Official title: A Single-Center, Multiple-dose, Randomized, Cross-Over, Double-Blind, Placebo-Controlled Study to Evaluate the Pharmacodynamics, Safety, and Tolerability of Oshadi Icp In Patients With Type 1 Diabetes Mellitus - Phase Ib Clinical Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Diabetes Mellitus, Insulin-Dependent, 1
Keywords: Diabetes Mellitus
Oral Insulin
Lead sponsor: Oshadi Drug Administration
Sponsor class: INDUSTRY
First posted: 2013-01-21
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Diabetes mellitus (DM) is a chronic disease of carbohydrate, fat, and protein metabolism caused by an absolute or relative deficiency of insulin, an anabolic hormone. The current methods of insulin therapy for diabetic patients are multiple daily injection therapy and continuous subcutaneous insulin infusion with an external pump. This rout of administration may lead to hyperinsulinemia as insulin is administered in a non physiological way, targeting mainly extra hepatic tissues (muscle, fat).

A method of providing insulin without the need for injections has been a goal in drug delivery.

Oshadi Drug Administration Ltd. has developed oral carrier for proteins based on biochemistry and quantum theory of biochemical reactions. The carrier enables the absorption of proteins from the gastrointestinal tract in their full structure. Oshadi has also developed the Oshadi Icp - insulin, proinsulin and C-peptide in Oshadi carrier, administrated orally. This study was design in order to evaluate the safety and feasibility of multiple administration of Oshadi Icp


Eligibility criteria: Inclusion Criteria:

* Type 1 diabetes mellitus (according to ADA criteria) for more than 1 year.
* Male/female 18 years old and older.
* BMI≥18.5 and ≤25
* Female of childbearing age must commit to avoid pregnancy and use contraception during the study.
* Patients must understand and be willing to give written informed consent prior to any study procedures or evaluations and be willing to adhere to all study schedules and requirements.

Exclusion Criteria:

* Any history of significant cardiac, renal, neurologic, metabolic, pulmonary, gastrointestinal, hematologic abnormality, chronic hepatic disease or any other disease which in the judgment of the investigator would interfere with the study or confound the results.
* Symptomatic DKA in the last 6 months
* Patients with positive HIV or HCV serology or positive HBsAg at screening.
* History or evidence of any active liver disease.
* History of epilepsy.
* One hypoglycemic seizure episode in the last six months or more than one hypoglycemic seizure episode in the last year.
* History of sever recurrent hypoglycemic unawareness.
* C-peptide \>3 mg/ml (fasting)
* Total average daily insulin dosage ≥1 IU/kg of body weight.
* Polycystic ovary syndrome
* Acanthosis nigricans
* 6.5% \> HbA1c or HbA1c \>10%
* eGFR\<60.
* Female patients who are breastfeeding or have a positive pregnancy test at screening or at any time during the study and not willing to practice birth control during study period.
* Inability to give written informed consent
* History of alcohol or drug abuse within 6 months of screening.
* Patients who have a positive urine drug screen for substances of abuse (benzodiazepine, THC, opiates, amphetamines, cocaine) at the screening.
* Mental disorders.
* Patients with poor venous access
* Significant swallowing disorders
* Digestive disorders
* Small bowel surgery
* Any intercurrent disease during the last week prior to screening which in the judgment of the investigator might affect blood glucose level.
* Any infectious disease developed during the 4 weeks prior to the study.
* Malabsorption disorders.
* Any significant abnormality by principal investigator in the baseline laboratory evaluation: liver and kidney functions, electrolytes, albumin, lipase, TSH, hemoglobin, white blood cell count and differential, platelets.

Primary outcomes:
measure: Adverse events and serious adverse events occurence
timeFrame: last follow-up visit (day 23)
Secondary outcomes:
measure: • To assess the pharmacodynamic effect of multiple doses of Oshadi Icp as measured by the area under the glucose concentration-time curve
timeFrame: last administration day (day 17)
Other outcomes:
measure: • Evaluating the total daily injected insulin dose during administration of Oshadi Icp vs. placebo
timeFrame: Last administration day (day 17)
Locations:
city: Zerifin
country: Israel
facility: Assaf-Harofeh Medical Center
Study officials:
References: